EBMT-EHA CAR-T 2019 | Future reseach; filling the CAR T-cell gaps
Speaking at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA) Nicolaus Kröger, MD University Medical Center Hamburg, Hamburg, Germany, explains how further research is neesed from both academia and the pharmaceutical industry to allow for comparison with autologous transplant and also to further investigate side effect and safety management.
Transcript (edited for clarity):
So the CAR T-cells is an exciting field. So the use is very limited so far in Europe. Yeah. The approval is coming from two phase two studies, this means there’s no randomization, so we need more studies, we need also academic studies, but studies also from the pharmaceutical industry, comparing this highly effective approach, from instance with autogenous transplantation in lymphoma, to compare it with other drugs in multiple myeloma and to compare it also with transplant activities and acute lymphoblastic leukemia.
But also to find the right place, so currently, the approval is in a very late stage. If patients are referred through a multiple relapse. And we need some studies to maybe use the drug because it’s very effective early in the treatment. And we have to learn to deal better with safety, with the side effects. And also if you hear carefully through the meeting, we had a lot of very interesting discussions. We had more than 90 abstracts here with young investigation and they showed out where the future from CAR T-cells is. So new development, new development in CAR T-cells, combining different anti targets, looking for other diseases, looking for the disease beyond hematology and oncology and even beyond oncology. Well, this is really a new avenue in the medical treatment of patients.
Get great new content delivered to your inboxSign up